Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56478 | 1.00 | CYP1A2 (0.55) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| SCHEMBL120603 | 1.00 | CYP1A2 (0.55) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| Hydrochloric Acid SCHEMBL28704563 | 0.98 | CYP1A2 (0.53) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| Bromide SCHEMBL28602504 | 0.98 | CYP1A2 (0.53) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| Hydrochloric Acid SCHEMBL2186508 | 0.98 | CYP1A2 (0.53) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| Hydrochloric Acid SCHEMBL28706049 | 0.98 | CYP1A2 (0.53) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| SCHEMBL756642 | 0.93 | LTA4H (0.52) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| SCHEMBL30913870 | 0.93 | ALOX5 (0.53) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| Propane SCHEMBL29187532 | 0.93 | CYP1A2 (0.55) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| Acetic Acid SCHEMBL11035019 | 0.88 | ALOX5 (0.49) | CYP1A2CYP2D6CYP2C19CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 835 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250078176-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2025-03-06 | — | — | US | claimed |
| US-20240327419-A1 | SYNTHESIS OF SUBSTITUTED TRICYCLIC AMIDES AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2024-10-03 | — | — | US | claimed |
| EP-4373823-A1 | SYNTHESIS OF SUBSTITUTED TRICYCLIC AMIDES AND ANALOGUES THEREOF | Arbutus Biopharma Corporation (CA) | 2024-05-29 | — | — | EP | claimed |
| CN-117730082-A | Synthesis of substituted tricyclic amides and analogs thereof | 爱彼特生物制药公司 | 2024-03-19 | — | — | CN | claimed |
| WO-2023117926-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2023-06-29 | — | — | WO | claimed |
| WO-2023002323-A1 | SYNTHESIS OF SUBSTITUTED TRICYCLIC AMIDES AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-01-26 | — | — | WO | claimed |
| CN-115073373-A | Method for asymmetric synthesis of (R) -5' -methoxy labdanin | 广东嘉博制药有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-114561440-B | Preparation method of high-purity (R) - (+) -1- (4-methoxyphenylethyl amine monomer | 天津全和诚科技有限责任公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114561440-A | Preparation method of high-purity (R) - (+) -1- (4-methoxyphenylethyl amine monomer | 天津全和诚科技有限责任公司 | 2022-05-31 | — | — | CN | claimed |
| CN-114163411-A | Preparation method of enantiomer pure dihydromyricetin | 宁波大学 | 2022-03-11 | — | — | CN | claimed |
| CN-109632921-B | Detection method for content of levofloxacin in levofloxacin bulk drug, electrochemical sensor used in detection method and chiral pyrrole compound | 嘉兴学院 | 2021-02-26 | — | — | CN | claimed |
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | claimed |
| US-8084630-B2 | Process for the synthesis of ramelteon and its intermediates | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-27 | — | — | US | claimed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | claimed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | claimed |
| EP-4714953-A1 | MELANOCORTIN 2-TYPE RECEPTOR ANTAGONIST | Scohia Pharma, Inc. (JP) | 2026-03-25 | — | — | EP | disclosed |
| EP-4695271-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | Merck Sharp & Dohme LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| CN-1035827-A | The 4-oxo of opticity-1-chromene-2-carboxylic acid derivative and intermediates preparation thereof | SANWA KAGAKU KENKYUSHO K K (JP) | 1989-09-27 | — | — | CN | disclosed |
| EP-0331078-A2 | Process for the preparation of optically active 4-oxo-1-benzopyran-2-carboxylic acid derivatives and intermediates thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | CYP1A2 5/4885CYP2D6 13/4885CYP2C19 76/4885 |
| US-20240327419-A1 | SYNTHESIS OF SUBSTITUTED TRICYCLIC AMIDES AND ANALOGUES THEREOF | HCCS, HDGF, GLS2 | CYP1A2 584/4885CYP2D6 324/4885CYP2C19 733/4885 |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | CYP1A2 6/4885CYP2D6 4/4885CYP2C19 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.